Matt Driedger1, Marie-Louise Vachon2, Alexander Wong3, Brian Conway4, Alnoor Ramji5, Sergio Borgia6, Ed Tam7, Lisa Barrett8, Dan Smyth8, Jordan J Feld9, Sam S Lee10, Curtis Cooper1. 1. Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. 2. Department of Medicine, Laval University, Quebec City, Quebec, Canada. 3. Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. 4. Department of Medicine, Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada. 5. Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 6. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 7. Department of Medicine, Liver Health Centre, Vancouver, British Columbia, Canada. 8. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 9. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 10. Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Abstract
Background: Alcohol use and hepatitis C virus (HCV) are two leading causes of liver disease. Alcohol use is prevalent among the HCV-infected population and accelerates the progression of HCV-related liver disease. Despite barriers to care faced by HCV-infected patients who use alcohol, few studies have analyzed uptake of direct-acting antiviral (DAA) treatment. Objective: We compared rates of treatment uptake and sustained virological response (SVR) between patients with and without alcohol use. Methods: Prospective data were obtained from the Canadian Network Undertaking against Hepatitis C (CANUHC) cohort. Consenting patients assessed for DAA treatment between January 2016 and December 2019 were included. Demographic and clinical characteristics were compared between patients with and without alcohol use by means of t-tests, χ2 tests, and Fisher's Exact Tests. Univariate and multivariate analyses were used to determine predictors of SVR and treatment initiation. Results: Current alcohol use was reported for 217 of 725 (30%) patients. The proportion of patients initiating DAA treatment did not vary by alcohol use status (82% versus 83%; p = 0.99). SVR rate was similar between patients with alcohol use and patients without alcohol use (92% versus 94%; p = 0.45). Univariate and multivariate analysis found no association between alcohol use and SVR or treatment initiation. Conclusion: Patients engaged in HCV treatment have highly favourable treatment uptake and outcomes regardless of alcohol use. Public health interventions should be directed toward facilitating access to care for all patients irrespective of alcohol use. Research into high-level alcohol use and DAA outcomes is needed.
Background: Alcohol use and hepatitis C virus (HCV) are two leading causes of liver disease. Alcohol use is prevalent among the HCV-infected population and accelerates the progression of HCV-related liver disease. Despite barriers to care faced by HCV-infected patients who use alcohol, few studies have analyzed uptake of direct-acting antiviral (DAA) treatment. Objective: We compared rates of treatment uptake and sustained virological response (SVR) between patients with and without alcohol use. Methods: Prospective data were obtained from the Canadian Network Undertaking against Hepatitis C (CANUHC) cohort. Consenting patients assessed for DAA treatment between January 2016 and December 2019 were included. Demographic and clinical characteristics were compared between patients with and without alcohol use by means of t-tests, χ2 tests, and Fisher's Exact Tests. Univariate and multivariate analyses were used to determine predictors of SVR and treatment initiation. Results: Current alcohol use was reported for 217 of 725 (30%) patients. The proportion of patients initiating DAA treatment did not vary by alcohol use status (82% versus 83%; p = 0.99). SVR rate was similar between patients with alcohol use and patients without alcohol use (92% versus 94%; p = 0.45). Univariate and multivariate analysis found no association between alcohol use and SVR or treatment initiation. Conclusion: Patients engaged in HCV treatment have highly favourable treatment uptake and outcomes regardless of alcohol use. Public health interventions should be directed toward facilitating access to care for all patients irrespective of alcohol use. Research into high-level alcohol use and DAA outcomes is needed.
Authors: M Eugenia Socías; Mohammad Karamouzian; Stephanie Parent; José Barletta; Kathleen Bird; Lianping Ti Journal: Int J Drug Policy Date: 2019-05-27
Authors: Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Patricia Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg Journal: Clin Gastroenterol Hepatol Date: 2018-03-11 Impact factor: 11.382
Authors: Jennifer V Campbell; Holly Hagan; Mary H Latka; Richard S Garfein; Elizabeth T Golub; Micaela H Coady; David L Thomas; Steffanie A Strathdee Journal: Drug Alcohol Depend Date: 2005-08-29 Impact factor: 4.492
Authors: Roy Nitulescu; Jim Young; Sahar Saeed; Curtis Cooper; Joseph Cox; Valerie Martel-Laferriere; Mark Hull; Sharon Walmsley; Mark Tyndall; Alexander Wong; Marina B Klein Journal: Int J Drug Policy Date: 2018-12-26
Authors: Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Edward R Cachay; Alvaro Mena; Luis Morano; Laura Benitez; Ivana Maida; Craig Ballard; Lucas Hill; Francesca Torriani; Angeles Castro; Elena Dore; Sheila Castro; Carmen de Mendoza Fernández; Vicente Soriano; Wm C Mathews Journal: Open Forum Infect Dis Date: 2019-02-11 Impact factor: 3.835
Authors: Christina Yek; Carolina de la Flor; John Marshall; Cindy Zoellner; Grace Thompson; Lisa Quirk; Christian Mayorga; Barbara J Turner; Amit G Singal; Mamta K Jain Journal: BMC Med Date: 2017-11-20 Impact factor: 8.775